Bristol-Myers offloads manufacturing plant to Catalent

BMS and Catalent disclosed the deal for the site in June, at which time they hoped to work through the regulatory approvals and union consultations needed to close the transaction by the end of the year. One week into 2020, Bristol-Myers revealed it had closed the deal. The deal covers a 19,300-square-meter manufacturing facility in Anagni, a town in central Italy, that lists cardiovascular, neuroleptics, anticancer, metabolic and anti-inflammatory medicines among the drugs it makes and packages. BMS used the facility to support its own product line but, as part of Catalent, the site will service multiple companies on a contract basis. Catalent will use the facility to provide biologic and oral solid dose manufacturing and packaging capacity to biopharma companies.